Daily tablets are accelerating the shift in the fast-growing market for GLP-1 weight-loss drugs.
Analysts expect the sector to approach $200bn by the early 2030s as pills attract new patients.
Novo Nordisk has launched the first oral version of Wegovy in the US.
Early demand has been strong, with prescriptions rising faster than for the original injection.
Patients say tablets are easier to take, cheaper and simpler to store.
Rival Eli Lilly is preparing its own pill, orforglipron.
Unlike Novo’s drug, it does not require fasting before use.
The competition is expected to make 2026 a decisive year for the obesity market.
Injections still produce greater weight loss and will remain important for severe obesity.
Pills are likely to draw people who are overweight or unwilling to use needles.
Falling prices and broader insurance coverage are also expanding access.
Obesity rates continue to climb worldwide, driving long-term demand.
Researchers say most eligible patients still receive no treatment.
The move from weekly jabs to daily tablets could push these drugs firmly into the mainstream.
